A Remarkable Case of Acute Motor-Sensory Axonal Polyneuropathy (AMSAN) Variant of Guillain Barré Syndrome, in a Diabetic Patient Infected With COVID-19: A Case Report and Review of the Literature.
COVID-19
Guillain-Barré syndrome
coronavirus
neuroelectrophysiological characteristics
neuroinfection
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
05
2022
accepted:
09
06
2022
entrez:
5
8
2022
pubmed:
6
8
2022
medline:
6
8
2022
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease- 2019 (COVID-19), has been a global epidemic in our healthcare system. SARS-CoV-2 primarily affects the respiratory system, but neurological involvement has also been reported, including Guillain-Barré syndrome (GBS) development. A 58-year-old male with known co-morbid hypertension and type 2 diabetes mellitus presented to the emergency room with complaints of worsening shortness of breath, dry cough, and fever for the past 10 days. On day 20 of hospitalization, he developed neurological symptoms after being tested positive for COVID-19. A neuroelectrophysiology study was conducted to evaluate neurological symptoms and suggested that the patient suffers from acute motor-sensory axonal polyneuropathy (AMSAN). CSF analysis showed elevated protein levels that confirmed the diagnosis of GBS. He was subsequently treated with oral prednisolone and IVIG, which improved neurological symptoms. Ever since the emergence of COVID-19, GBS has surfaced as to its potentially dangerous outcome. Healthcare professionals should be mindful of GBS and should rule it out in anyone having sensory symptoms or weakness during or after a COVID-19 infection. Its early detection and treatment can result in improved clinical outcomes.
Sections du résumé
Background
UNASSIGNED
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease- 2019 (COVID-19), has been a global epidemic in our healthcare system. SARS-CoV-2 primarily affects the respiratory system, but neurological involvement has also been reported, including Guillain-Barré syndrome (GBS) development.
Case Presentation
UNASSIGNED
A 58-year-old male with known co-morbid hypertension and type 2 diabetes mellitus presented to the emergency room with complaints of worsening shortness of breath, dry cough, and fever for the past 10 days. On day 20 of hospitalization, he developed neurological symptoms after being tested positive for COVID-19. A neuroelectrophysiology study was conducted to evaluate neurological symptoms and suggested that the patient suffers from acute motor-sensory axonal polyneuropathy (AMSAN). CSF analysis showed elevated protein levels that confirmed the diagnosis of GBS. He was subsequently treated with oral prednisolone and IVIG, which improved neurological symptoms.
Conclusion
UNASSIGNED
Ever since the emergence of COVID-19, GBS has surfaced as to its potentially dangerous outcome. Healthcare professionals should be mindful of GBS and should rule it out in anyone having sensory symptoms or weakness during or after a COVID-19 infection. Its early detection and treatment can result in improved clinical outcomes.
Identifiants
pubmed: 35928139
doi: 10.3389/fneur.2022.937989
pmc: PMC9344130
doi:
Types de publication
Case Reports
Langues
eng
Pagination
937989Informations de copyright
Copyright © 2022 Ali, Karam, Lalani, Jawed, Moin, Douba and Ali.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
EClinicalMedicine. 2020 Jun 26;24:100433
pubmed: 32766542
Neurol Sci. 2020 Jul;41(7):1657-1658
pubmed: 32468450
J Med Case Rep. 2013 Sep 10;7:223
pubmed: 24228906
Caspian J Intern Med. 2021;12(Suppl 2):S451-S459
pubmed: 34760104
Arch Neurol. 2004 Nov;61(11):1669-73
pubmed: 15534177
Neuroepidemiology. 2011;36(2):123-33
pubmed: 21422765
Arch Iran Med. 2020 Oct 01;23(10):718-721
pubmed: 33107316
Front Neurol. 2020 Aug 21;11:909
pubmed: 32973665
Lancet Neurol. 2020 May;19(5):383-384
pubmed: 32246917
Cureus. 2021 Oct 30;13(10):e19154
pubmed: 34868787
Eur J Neurol. 2016 Mar;23(3):439-46
pubmed: 26511168
Rev Neurol (Paris). 2020 Jun;176(6):518-519
pubmed: 32359804
J Med Case Rep. 2021 Jul 16;15(1):379
pubmed: 34271989
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33837054
Neurol Neuroimmunol Neuroinflamm. 2020 Apr 29;7(4):
pubmed: 32350026
N Engl J Med. 2020 Jun 25;382(26):2574-2576
pubmed: 32302082
Ann Neurol. 2021 Mar;89(3):598-603
pubmed: 33295021
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375
J Clin Neurosci. 2020 Jun;76:233-235
pubmed: 32312628
Int Med Case Rep J. 2021 Apr 20;14:251-253
pubmed: 33907474
J Neuroimmunol. 2021 Jul 15;356:577590
pubmed: 33957540
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102326
pubmed: 34731822